Introduction {#s1}
============

Multiple myeloma (MM) is one of the most common hematologic malignancies with poor prognosis, characterized by neoplastic proliferation of monoclonal plasma cells. The incidence of MM in developed countries is about 5--7 cases per 100 000 individuals [@pone.0091461-Kyle1]. Despite extensive research efforts over the last two decades, the risk factors of MM remain to be established. Numerous case-control and cohort studies to date have suggested that several environmental factors may be associated with the risk of MM, such as ionizing radiation [@pone.0091461-Cuzick1], benzene [@pone.0091461-Infante1] and agricultural occupation [@pone.0091461-Blair1]. The relationship between autoimmune disease and hematopoietic malignancies was initially postulated in 1964 [@pone.0091461-Lea1]. However, the issue of whether autoimmune diseases increase the incidence of MM remains controversial.

On the basis of animal models of MM, it is suggested that repeated antigenic stimulation of the immune system plays an important role in MM development [@pone.0091461-Potter1], [@pone.0091461-Radl1]. A number of studies have confirmed an association of lymphoma with autoimmune conditions [@pone.0091461-Smedby1]--[@pone.0091461-Gridley1], including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and autoimmune hemolytic anemia, although the underlying pathogenesis is unclear. Similarly, the relationship between MM and autoimmune disease has been a long-term subject of investigation, but inconsistent results have been obtained to date.

The main aim of this meta-analysis was to estimate the comparative risk of developing MM in RA patients versus the general population. Two additional goals were (1) to explore the variation in the association of RA and MM among subgroups of interest and (2) to investigate if there is an association between MM and other autoimmune diseases.

Methods {#s2}
=======

Search Strategy {#s2a}
---------------

A literature search was conducted with PubMed (from January 1, 1951), EMBASE (from January 1, 1955) and Web of Science (from January 1, 1970) using the following search terms: rheumatoid arthritis, autoimmune disease, etiology, epidemiology, risk factors, multiple myeloma, cancer, malignancy. The final search strategy in PubMed was attached as appendix. The last literature search was performed on December 25, 2013. We also searched annual meeting abstracts of the American Society of Hematology from 2004 to 2013 to identify eligible unpublished data. All references cited in the retrieved articles were additionally reviewed to indentify additional eligible studies. Inclusion criteria were as follows: human participants without limitation of sex or geographic location, case-control or cohort studies, prior medical history of RA as exposure, MM as outcome, studies that reported relative risk (RR), standardized incidence ratio (SIR) or odds ratio (OR) of MM patients with prior history of RA, publication in English. In addition, the selection of cohort studies for inclusion was made regardless of specific RA management strategies. When duplicate reports for the same population and data source were eligible, we chose the original reports with the largest sample size. Case series, case reports, in vitro and animal studies were excluded. Eligibility assessment was performed independently by two reviewers, and disagreements resolved by consensus.

Data Extraction {#s2b}
---------------

Two authors performed data extraction independently, and any discrepancies were addressed by discussion and re-evaluation. We obtained information on the author, year of publication, country of origin, source of case, control and cohort, controlled factors, diagnosis criteria and treatment regimen for RA. Cohort size, number of cases, cohort duration, SIR and 95% confidence intervals (CIs) or sufficient data to allow calculation of these numbers were additionally necessary for cohort studies. For case-control studies, the exact numbers of cases and controls by RA, OR and 95% CIs were required. For the purpose of ascertaining the relationship between MM and other autoimmune diseases, related data were recorded, where available, according to the above extraction principles.

The Newcastle-Ottawa Scale (NOS), developed for evaluating the quality of nonrandomized studies [@pone.0091461-Wells1], was used by two independent reviewers to assess the methodological quality of each study, and the scores subsequently used in subgroup analysis. A score of ≤5 was considered as relative low quality [@pone.0091461-Beranger1].

Statistical Analyses {#s2c}
--------------------

In case-control studies, OR and 95% CIs for MM risk factors were directly extracted from original research papers or calculated when not provided. The primary outcome for cohort studies was SIR and corresponding 95% CI. In cases where SIRs were not specifically reported, calculations were made from the number of observed MM divided by the number of expected cases in the general population provided by authors, and 95% CI determined using the standard error of the natural logarithm of SIR, estimated from the inverse of the square root of the observed number of cases. The measure of interest was RR, estimated from ORs in case-control studies and SIRs in cohort studies. Since the incidence of MM is low, SIR and OR produce similar estimate of RR, thus we present all results as RR for simplicity [@pone.0091461-Greenland1]--[@pone.0091461-Larsson1]. Between-study heterogeneity was examined using a chi-square test of heterogeneity and *I* ^2^ measure of inconsistency. P-values less than 0.1 or the *I* ^2^ statistic greater than 50% were considered statistically significant [@pone.0091461-Higgins1]. Under these conditions, data were pooled based on the method of Dersimonian and Laird under a random effects model otherwise under fixed effects model. Two-tailed p≤0.05 was considered statistically significant for all analyses.

To evaluate publication bias, we constructed a funnel plot and applied Begg's test. Trim and Fill analysis was used to estimate the number of missing studies and their potential effects on outcomes. Sensitivity analyses were additionally conducted to ascertain the robustness of our findings. The influence of RA was examined by excluding studies restricted to elderly patients (≥65 years) or single-sex participants and those that failed to control important confounders. All meta-analyses were conducted with Stata 12.0.

Results {#s3}
=======

Abstract evaluation yielded thirty-two potential studies for analysis ([Figure 1](#pone-0091461-g001){ref-type="fig"}), of which five [@pone.0091461-Doody1]--[@pone.0091461-Chen1] were excluded, since they failed to provide sufficient data for calculation. Twenty-three case-control and cohort studies were included after full text assessment. Another two publications [@pone.0091461-Anderson1], [@pone.0091461-Pearce1] were incorporated after examining references from the extracted articles. Among the 25 studies, seven [@pone.0091461-Gridley1], [@pone.0091461-Eriksson1]--[@pone.0091461-Hakulinen1] were subsequently excluded for overlap in case or cohort resources. Consequently, our meta-analysis consisted of eight [@pone.0091461-Anderson1], [@pone.0091461-Pearce1], [@pone.0091461-Cohen1]--[@pone.0091461-Lindqvist1] case-control and ten [@pone.0091461-Thomas1], [@pone.0091461-Isomaki2]--[@pone.0091461-Hemminki2] cohort studies.

![Flow diagram depicting the identification and selection of eligible case-control and cohort studies.](pone.0091461.g001){#pone-0091461-g001}

All the studies published from 1982 to 2013 were performed in USA or Europe, except one case- control study from New Zealand [@pone.0091461-Pearce1]. There was slight overlap in the patient populations of two studies [@pone.0091461-Isomaki2], [@pone.0091461-Kauppi1] from Finland. Landgren et al. [@pone.0091461-Landgren3] limited the study subjects to women, while the groups of Pearce [@pone.0091461-Pearce1] and Brown [@pone.0091461-Brown1] mainly focused on the role of prior autoimmune disorders in male MM. The NOS scores varied from 5 to 7 in all case-control studies, with the exception of the reported score of 3 by Landgren and co-workers [@pone.0091461-Landgren3] as a result of unsatisfactory comparability. Since almost all the cohort studies used the expected cancer incidence calculated from national cancer rates as a comparison instead of the non-exposed cohort, NOS scores were relatively low, ranging from 4 to 5.

In the eight case-control studies, OR was all obtained from the published articles or calculated from the numbers of cases and controls by RA. In four cohort studies [@pone.0091461-Thomas1], [@pone.0091461-Isomaki2], [@pone.0091461-ParikhPatel1], [@pone.0091461-Dreyer1], the SIRs and 95% CIs were estimated from the number of observed MM and expected MM incidence provided by authors, while others were directly extracted from the original article. Only three studies [@pone.0091461-Setoguchi1], [@pone.0091461-Herrinton1], [@pone.0091461-Dreyer1] reported the type of treatment for RA before MM diagnosis. All important information is presented in [Tables 1](#pone-0091461-t001){ref-type="table"} and [2](#pone-0091461-t002){ref-type="table"}.

10.1371/journal.pone.0091461.t001

###### Characteristics of case-control studies enrolled in the meta-analysis.

![](pone.0091461.t001){#pone-0091461-t001-1}

  Author          Year     Country     Sex    Controls    Cases   Controls   OR (95% CI)   Controlled Factors                      
  -------------- ------ ------------- ----- ------------ ------- ---------- ------------- -------------------- ------------------- ---------------------------------------------
  Pearce NE       1986   New Zealand    M    Population     4        72           7               308           2.30 (0.60--8.00)             Age, registration year
  Cohen HJ        1987       USA       M+F    Hospital     62        91          203              210           0.70 (0.48--1.03)        Age, gender, race, disease status
  Boffetta P      1989       USA       M+F   Population    39        89          164              348           0.90 (0.60--1.50)          Age, gender, race, residence
  Lewis DR        1994       USA       M+F   Population    64       509          241             1 890          0.80 (0.60--1.10)                Age, gender, race
  Vlajinac HD     2003   Yugoslavia    M+F    Hospital     12        85           5                95           2.60 (0.90--7.60)             Age, gender, residence
  Landgren O      2006       USA        F    Population     7       172           9               682           2.30 (0.80--6.50)                      none
  Anderson LA     2009       USA       M+F   Population    263     9 211        3 289           119 242         1.00 (0.90--1.10)   Gender, year of diagnosis, age at diagnosis
  Lindqvist EK    2011     Sweden      M+F   Population    111     19 001        567             74 841         0.80 (0.60--0.90)             Age, gender, residence

Abbreviations: RA, rheumatoid arthritis; OR, odds ratio; CI, confidence intervals; M, male; F, female.

10.1371/journal.pone.0091461.t002

###### Characteristics of cohort studies enrolled in the meta-analysis.

![](pone.0091461.t002){#pone-0091461-t002-2}

  Author            Year   Country   Sex   Cohort Size   Number of MM     SIR (95% CI)      Follow-up Duration (PY)
  ---------------- ------ --------- ----- ------------- -------------- ------------------- -------------------------
  Isomaki HA        1982   Finland   M+F     46 101           28        2.20 (1.52--3.19)           213 911
  Mellemkjaer L     1996   Denmark   M+F     20 699           21        1.10 (0.70--1.70)           144 421
  Kauppi M          1997   Finland   M+F      9 469           8         1.20 (0.50--2.30)           65 391
  Thomas E          2000   England   M+F     26 623           38        1.66 (1.21--2.28)           151 987
  Setoguchi S       2006     USA     M+F      7 830           19        2.00 (1.26--3.12)           33 410
  Herrinton LJ      2008     USA     M+F      2 982           2         2.36 (0.28--8.50)            7 791
  Brown LM          2008     USA      M        --             94        1.17 (0.94--1.45)          27 years
  Parikh-Patel A    2009     USA     M+F     84 475           64        0.90 (0.70--1.15)           405 540
  Hemminki K        2012   Sweden    M+F     72 309           81        0.88 (0.70--1.09)           731 954
  Dreyer L          2013   Denmark   M+F      7 159           4         1.76 (0.66--4.69)           24 811

Abbreviations: M, male; F, female; MM, multiple myeloma; SIR, standardized incidence ratio; CI, confidence intervals; PY, person years.

--: Not mentioned.

The RRs of MM for RA versus non-RA patients overall and by study design was presented ([Figure 2](#pone-0091461-g002){ref-type="fig"}). The random-effects pooled RRs for MM were 1.32 (95% CI, 1.04--1.67) for cohort studies and 0.92 (95% CI, 0.77--1.11) for case-control studies. Compared with non-RA patients, RA patients showed an RR of 1.14 (95% CI, 0.97--1.33) regardless of study type, possibly suggesting lack of association between RA and MM. However, overall analysis revealed significant between-study heterogeneity (p\<0.1; *I* ^2^ = 71.5%).

![Forest plot of studies on multiple myeloma development risk in rheumatoid arthritis.](pone.0091461.g002){#pone-0091461-g002}

Sensitivity analysis was presented in [Table 3](#pone-0091461-t003){ref-type="table"}. After excluding studies restricted to elderly patients (≥65 years) or single-sex participants and those that failed to adjust important factors, overall RR decreased slightly to 1.09, 1.11 and 1.11, respectively.

10.1371/journal.pone.0091461.t003

###### Sensitivity analysis of the association between multiple myeloma and rheumatoid arthritis according to different exclusion criteria.

![](pone.0091461.t003){#pone-0091461-t003-3}

  Studies included                                                                             Studies (N)      RR (95% CI)      p value   *I* ^2^ (%)
  ------------------------------------------------------------------------------------------- ------------- ------------------- --------- -------------
  All studies                                                                                      18        1.14 (0.97--1.33)   \<0.001      71.5
  Studies without age restriction of participants[a](#nt104){ref-type="table-fn"}                  17        1.09 (0.94--1.27)   \<0.001      68.7
  Studies with both male and female participants[b](#nt105){ref-type="table-fn"}                   15        1.11 (0.94--1.32)   \<0.001      74.1
  Studies that controlled for important confounding factors[c](#nt106){ref-type="table-fn"}        16        1.11 (0.95--1.30)   \<0.001      73.1

Excludes the study by the group of Setoguchi [@pone.0091461-Setoguchi1].

Excludes studies by the groups of Pearce [@pone.0091461-Pearce1], Landgren [@pone.0091461-Landgren3] and Brown [@pone.0091461-Brown1].

Excludes studies by the groups of Pearce [@pone.0091461-Pearce1] and Landgren [@pone.0091461-Landgren3].

Abbreviations: N, number; RR, relative risk; NS, not significant; CI, confidence interval.

To investigate the source of heterogeneity, subset analysis by study design, publication year, study quality, geographic region, control type and average follow-up duration was conducted. Statistical association between RA and MM was only found to be significant in studies with relatively low quality (RR = 1.29, 95% CI, 1.02--1.64) and cohort studies with relatively low quality (RR = 1.36, 95% CI, 1.02--1.81). Overall, in studies with relatively higher quality according to NOS, as well as those published after 2000, RA was not associated with increase in MM risk (RR = 0.95, 95% CI, 0.79--1.14 and RR = 1.15, 95% CI 0.96--1.37, respectively). Notably, subgroup analyses failed to define the reason for heterogeneity ([Table 4](#pone-0091461-t004){ref-type="table"}).

10.1371/journal.pone.0091461.t004

###### Meta-analysis of multiple myeloma incidence by subgroup.

![](pone.0091461.t004){#pone-0091461-t004-4}

                                     Subgroup                        Analyses (N)        RR (95% CI)      p-value   *I* ^2^ (%)
  -------------- ------------------------------------------------ ------------------ ------------------- --------- -------------
  Overall                          Study design                      Cohort (10)      1.32 (1.04--1.67)   \<0.001      72.9
                                                                   Case-control (8)   0.92 (0.77--1.11)    0.031       54.6
                                 Publication year                  Before 2000 (7)    1.10 (0.77--1.59)   \<0.001      75.7
                                                                   After 2000 (11)    1.15 (0.96--1.37)   \<0.001      71.3
                                  Study quality                       NOS≤5 (13)      1.29 (1.02--1.64)   \<0.001      72.7
                                                                      NOS\>5 (5)      0.95 (0.79--1.14)    0.024       64.3
                      Region[a](#nt109){ref-type="table-fn"}           USA (9)        1.02 (0.86--1.22)    0.008       61.4
                                                                      Europe (8)      1.30 (0.93--1.79)   \<0.001      80.9
  Cohort                         Publication year                  Before 2000 (3)    1.48 (0.90--2.45)    0.047       67.3
                                                                    After 2000 (7)    1.25 (0.96--1.61)    0.002       72.0
                                  Study quality                       NOS≤5 (9)       1.36 (1.02--1.81)   \<0.001      75.9
                                                                      NOS\>5 (1)      1.17 (0.94--1.45)     --          --
                                      Region                           USA (4)        1.25 (0.89--1.77)    0.017       70.4
                                                                      Europe (6)      1.37 (0.95--1.97)   \<0.001      77.7
                  Mean follow-up[b](#nt110){ref-type="table-fn"}    \<5 years (5)     1.63 (0.97--2.74)   \<0.001      80.4
                                                                     ≥5 years (4)     1.17 (0.82--1.66)    0.015       71.2
  Case-control                   Publication year                  Before 2000 (4)    0.81 (0.65--1.02)    0.352        8.1
                                                                    After 2000 (4)    1.02 (0.77--1.36)    0.021       69.1
                                  Study quality                       NOS≤5 (4)       1.14 (0.71--1.83)    0.060       59.5
                                                                      NOS\>5 (4)      0.88 (0.71--1.10)    0.046       62.5
                      Region[a](#nt109){ref-type="table-fn"}           USA (5)        0.91 (0.74--1.11)    0.116       45.9
                                                                      Europe (2)      1.28 (0.41--3.96)    0.033       77.9
                                   Control type                     Population (6)    0.92 (0.78--1.10)    0.088       47.8
                                                                     Hospital (2)     1.22 (0.34--4.36)    0.023       80.6

Abbreviations: N, number; M, male; F, female; RR, relative risk; NOS, Newcastle-Ottawa Scale.

One case-control study conducted in New Zealand was excluded from analysis.

One study with unknown mean follow-up duration was excluded from analysis.

--: Cannot be calculated.

Publication bias in this meta-analysis was suspected as indicated from the funnel plot and Begg's test (p = 0.081). However, RR values remained similar after Trim and Fill correction for possible missing data (RR = 1.14, 95% CI 0.97--1.33 before Trim and Fill versus RR = 1.09, 95% CI 0.93--1.27 after Trim and Fill) ([Figure 3](#pone-0091461-g003){ref-type="fig"}).

![Funnel plot for case-control and cohort studies (dots: original data; squares: filled data).](pone.0091461.g003){#pone-0091461-g003}

The reported relevance of other autoimmune diseases, including pernicious anemia and ankylosing spondylitis (AS), in MM incidence is presented ([Figure 4](#pone-0091461-g004){ref-type="fig"}). Patients with pernicious anemia and AS displayed a 1.31- to 1.65-fold and 1.36- to 2.30-fold increase in MM risk, respectively. In contrast, MM development appeared to be unrelated to prior medical history of psoriasis (RR = 0.91, 95% CI, 0.78*--*1.05), SLE (RR = 1.18, 95% CI, 0.88--1.60), Sjögren syndrome (SS) (RR = 1.22, 95% CI 0.83--1.78) or polymyositis/dermatomyositis (RR = 1.37, 95% CI 0.86--2.17). The between-study heterogeneity analyses were all not statistically significant.

![Forest plot of studies on multiple myeloma development risk in pernicious anemia and AS.](pone.0091461.g004){#pone-0091461-g004}

Discussion {#s4}
==========

Our meta-analysis results suggest that MM seems not more common in patients with a past history of RA, consistent with our sensitivity data. However, subgroup analysis revealed that RA patients are more likely to suffer from subsequent MM in cohort studies (RR = 1.32, 95% CI 1.04--1.67). Information on prior autoimmune diseases in case-control studies was mostly obtained from self-reports through interviews or questionnaires, while in cohort studies, investigators relied mainly on linkage records, which probably attributed to the differences between the two types of studies. Notably, subset analysis confirmed that statistical association between RA and MM was only significant in studies with NOS score≤5, further indicating that RA might not act as risk factor for MM.

A number of studies have explored whether repeated or chronic antigenic stimulation leads to hematopoietic malignancies. Some researchers [@pone.0091461-Hakulinen1] reported elevated risk for MM in patients with RA, while others [@pone.0091461-Gramenzi1], [@pone.0091461-Cuzick2] reached different conclusions. An antigenic stimulation hypothesis was proposed to explain the excessive risk of MM in patients with autoimmune diseases. Chronic immune stimulation resulting from autoimmune disorders, with its associated lymphocyte activation, tends to induce uncontrolled proliferation of malignant plasma cells, leading to MM [@pone.0091461-Symmons1]. Since no biologic marker has been developed that can effectively measure lifetime immune stimulation, this theory remains controversial. Meanwhile, evidence from previous studies indicates that increased risk could be a consequence of therapy, rather than the disease itself. For instance, higher risk of non-Hodgkin's lymphoma and MM has been reported following use of steroids [@pone.0091461-Landgren3], [@pone.0091461-Holly1], which are important for autoimmune disease treatment. Similarly, cytotoxic and immunosuppressive drugs may suppress immunodefense against malignant cells and lead to oncogenesis [@pone.0091461-Bachman1]. Moreover, there may be a common genetic or environmental susceptibility in autoimmune diseases and plasma cell tumors, or undiagnosed MM may manifest with clinical features that mimic connective tissue diseases. Taking our current results and the above studies into account, the credibility of the antigenic stimulation hypothesis is called into question.

Only one cohort study [@pone.0091461-Mellemkjaer2] investigated the effect of the duration of follow-up on the risk of MM and determined that the borderline excess of MM was confined to the early 4-year follow-up. Thomas [@pone.0091461-Thomas1] proposed that although increased risk of MM persisted for hematopoietic cancers throughout the follow-up period, the greatest excess was within the first 3 months after hospitalization. These findings could possibly indicate a common etiologic factor for RA and MM, or further prove the association confirmed in above two studies might be resulted from detection bias. With the current common application of anti-TNF drugs, concern has been raised about the risk of developing malignancy related with their use [@pone.0091461-Bongartz1]. However, as implied from two studies mentioned earlier [@pone.0091461-Setoguchi1], [@pone.0091461-Dreyer1], there was no significant increase in the risk of MM among anti-TNF users. Considering the small number of reports available, further studies are warranted to account for this potential confounder when examining the relationship of autoimmune diseases and MM.

Meta-analysis results revealed that pernicious anemia is another risk factor for MM, consistent with several prior epidemiologic studies [@pone.0091461-Hsing1], [@pone.0091461-Brinton1]. The related pathogenesis may involve immune alterations or chromosome abnormalities in the bone marrow of patients with pernicious anemia [@pone.0091461-Brinton1]. On the other hand, vitamin B12 deficiency caused by pernicious anemia may promote MM development by disrupting normal homeostasis for one-carbon metabolism [@pone.0091461-Friso1]. The lack of association of MM with psoriasis, SLE, SS, and polymyositis/dermatomyositis raises the question of whether oncogenesis is dependent on the type of autoimmune disease. A number of studies evaluating the risk of MM in AS [@pone.0091461-Brown1] and polymyalgia rheumatic [@pone.0091461-Lindqvist1] patients have reported positive associations, similar to our assessment of AS and MM. Assumptions such as whether an autoimmune disease resulting in MM is associated with disease activity, amount of autoantibody, and the extent of organ involvement should be examined. Although the current meta-analysis presents a more precise estimate of MM risk in RA patients than individual studies, significant heterogeneity remains a primary limitation of our study. Subgroup analyses failed to determine the source of heterogeneity. The diversity of subject sources and study methodologies may have led to inconsistencies. One such example is the study by Boffetta [@pone.0091461-Boffetta1] including 282 patients that died from MM, meaning that they were likely to suffer from more severe diseases and past medical history obtained from their family members was possibly incomplete. Similarly, another study [@pone.0091461-Setoguchi1] was restricted to subjects older than 65 years whose disease spectrum may be distinct from that of the general population. The variable proportions of races in different studies may additionally contribute to significant heterogeneity. Moreover, misclassification of patients may have occurred in case-control studies, since no consistent diagnosis criteria were applied by investigators and most enrollments were dependent on reports and certificates, rather than specific laboratory data, similar to enrollment in cohort studies. As indicated in cohort studies, RA patients may develop MM after more than 20 years, in which case recall bias may exist in case-control studies.

Another limitation of this study is that certain articles had to be excluded, since no data on MM and RA were available, although their relationship was evaluated. Exclusion of such studies may have led to results bias. In spite of this, the possible bias might not be so evident, since why these data were not reported mostly lied in that authors found no specific association between RA and MM. Although publication bias was borderline significant as indicated by Begg's test, adjustment for possibly missing manuscripts yielded similar results, strongly supporting the robustness of our analyses.

Conclusion {#s4a}
----------

Despite its limitations, our meta-analysis provides novel evidence for increased MM development risk in AS and pernicious anemia, although the underlying pathogenesis remains controversial. Notably, RA does not appear to alter the risk of MM, while between-study heterogeneity suggested caution in the interpretation of results. Further large-scale longitudinal studies containing details of risk factors and treatment information are necessary to determine the pathophysiological mechanism linking autoimmune diseases and MM. Moreover, identification of reliable exposure biomarkers of immune stimulation would be significantly beneficial.

Supporting Information {#s5}
======================

###### 

**Search strategy for PubMed.**

(DOCX)

###### 

Click here for additional data file.

###### 

**PRISMA 2009 Checklist for current meta-analysis.**

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: KNS GFX QW DBZ JL. Performed the experiments: KNS GFX QW JL. Analyzed the data: KNS GFX QW JL. Contributed reagents/materials/analysis tools: JL. Wrote the paper: KNS GFX QW.
